The NSCLC patients with ALK fusion mutation can be divided into three groups: patients only had ALK fusion mutation (ALK+), patients had ALK fusion mutation coexisting with EGFR mutation (ALK + EGFR), and patients had ALK fusion mutation coexisting with TP53 mutation (ALK + TP53). This evidence concerns the gene TP53 and non-small cell lung carcinoma.